UPDATE 1-Par Pharma gets subpoena on unit's promotional practice

* Says DoJ probing promotional practices for Megace

* Says company intends to cooperate with DoJ

March 27 (Reuters) - Par Pharmaceutical Cos Inc (PRX.N) said the United States Department of Justice is currently investigating promotional practices of its unit in the sales of its appetite-stimulant Megace.

In a regulatory filing, the company said it received a subpoena from the department, requesting documents related to Megace, and it intended to fully cooperate with the inquiry.

Megace is a brand name product of Strativa Pharmaceuticals, a division of its unit.

Shares of the Woodcliff Lake, New Jersey-based company closed down 12 percent at $9.85 Friday on the New York Stock Exchange. (Reporting by Vidya L Nathan in Bangalore; Editing by Vinu Pilakkott)